Evidence map›Paper›PMID 12761626›Full record

ReviewInternational archives of occupational and environmental health2003

Skin protection and percutaneous absorption of chemical hazards.

H Drexler

Abstract readReview
PubMed Publisher
In one paragraph

Review in International archives of occupational and environmental health, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.1field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

H DrexlerDepartment and Outpatient Clinic of Occupational, Social and Environmental Medicine, Friedrich-Alexander University of Erlangen-Nuremberg, Schillerstrasse 25/29, 91054 Erlangen, Germany. Hans.Drexler@rzmail.uni-erlangen.de
Friedrich-Alexander-Universität Erlangen-Nürnberg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hazardous substances that penetrate the skin barrier may induce dermal irritation, inflammation or sensitisation, as well as systemically toxic effects. Air threshold limits are insufficient to prevent adverse health effects in the case of contact with substances with a high dermal absorption potential. Biological monitoring is a useful tool to quantify internal exposure of an individual and allows an assessment to be made of the dermal absorption pathway. Additionally, the efficacy of protective equipment can be proved. Standard gloves are ineffective to decrease dermal uptake. Various skin-care products include emulgators, which are used as penetration enhancers in transdermal therapeutic drugs. Hence, specific skin-care products potentially enhance dermal absorption of certain chemicals. On the other hand, the best protection from dermal absorption is the physiological skin barrier-the stratum corneum. Skin-care products that accelerate regeneration of the stratum corneum are obliged to have positive effects to prevent dermal absorption. With regard to the increasing number of occupational skin diseases and the large quantity of skin-care products that are used at workplaces it is essential that the mechanism of protection and efficacy be assessed. In the future, we require evidence-based prevention or evidence-based medicine that includes evidence-based prevention.

Indexed as

Dermatitis, OccupationalDermatologic AgentsEnvironmental MonitoringGloves, ProtectiveHazardous SubstancesHumansOccupational ExposureOccupational MedicineSkin AbsorptionSkin CareDermatologic AgentsHazardous Substances

Identifiers

PMID12761626
OpenAlexW1987495306

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.